Daclatasvir: potential role in hepatitis C

References

• Shepard CW Finelli L Alter MJ Global epidemiology of hepatitis C virus infection Lancet Infect Dis 2005 5 10 558 567 16122679
   PubMed Web of Science ®Google Scholar
• Alter MJ Epidemiology of hepatitis C virus infection World J Gastroenterol 2007 13 17 2436 2441 17552026
   PubMed Web of Science ®Google Scholar
• Alter MJ Kruszon-Moran D Nainan OV The prevalence of hepatitis C virus infection in the United States, 1988 through 1994 N Engl J Med 1999 341 8 556 562 10451460
   PubMed Web of Science ®Google Scholar
• Di Bisceglie AM Natural history of hepatitis C: its impact on clinical management Hepatology 2000 31 4 1014 1018 10733560
   PubMed Web of Science ®Google Scholar
• Armstrong GL Wasley A Simard EP McQuillan GM Kuhnert WL Alter MJ The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 Ann Intern Med 2006 144 10 705 714 16702586
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM The results of Phase III clinical trials with telaprevir and boceprevir presented at the Liver Meeting 2010: a new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending Gastroenterology 2011 140 3 746 754 21255572
   PubMedGoogle Scholar
• Gentile I Viola C Reynaud L Hemolytic anemia during pegylated IFN-alpha2b plus ribavirin treatment for chronic hepatitis C: ribavirin is not always the culprit J Interferon Cytokine Res 2005 25 5 283 285 15871666
   PubMed Web of Science ®Google Scholar
• Hegade VS Sood R Saralaya D Moreea S Pulmonary complications of treatment with pegylated interferon for hepatitis C infection-two case reports Ann Hepatol 2013 12 4 629 633 23813142
   PubMed Web of Science ®Google Scholar
• Slavenburg S Heijdra YF Drenth JP Pneumonitis as a consequence of (peg)interferon-ribavirin combination therapy for hepatitis C: a review of the literature Dig Dis Sci 2010 55 3 579 585 19399621
   PubMed Web of Science ®Google Scholar
• Tosone G Borgia G Gentile I A case of pegylated interferon alpha-related diabetic ketoacidosis: can this complication be avoided? Acta Diabetol 2007 44 3 167 169 17721757
   PubMed Web of Science ®Google Scholar
• Liang TJ Rehermann B Seeff LB Hoofnagle JH Pathogenesis, natural history, treatment, and prevention of hepatitis C Ann Intern Med 2000 132 4 296 305 10681285
   PubMedGoogle Scholar
• Zeuzem S Feinman SV Rasenack J Peginterferon alfa-2a in patients with chronic hepatitis C N Engl J Med 2000 343 23 1666 1672 11106715
   PubMed Web of Science ®Google Scholar
• Grakoui A McCourt DW Wychowski C Feinstone SM Rice CM A second hepatitis C virus-encoded proteinase Proc Natl Acad Sci U S A 1993 90 22 10583 10587 8248148
   PubMed Web of Science ®Google Scholar
• Grakoui A Wychowski C Lin C Feinstone SM Rice CM Expression and identification of hepatitis C virus polyprotein cleavage products J Virol 1993 67 3 1385 1395 7679746
   PubMed Web of Science ®Google Scholar
• Lee C Interaction of Hepatitis C Virus Core Protein with Janus Kinase Is Required for Efficient Production of Infectious Viruses Biomol Ther (Seoul) 21 97 106 24009866
   PubMed Web of Science ®Google Scholar
• Moradpour D Penin F Rice CM Replication of hepatitis C virus Nat Rev Microbiol 2007 5 6 453 463 17487147
   PubMed Web of Science ®Google Scholar
• Blight KJ Kolykhalov AA Rice CM Efficient initiation of HCV RNA replication in cell culture Science 2000 290 5498 1972 1974 11110665
   PubMed Web of Science ®Google Scholar
• Lohmann V Körner F Koch J Herian U Theilmann L Bartenschlager R Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line Science 1999 285 5424 110 113 10390360
   PubMed Web of Science ®Google Scholar
• Lee C Discovery of hepatitis C virus NS5A inhibitors as a new class of anti-HCV therapy Arch Pharm Res 2011 34 9 1403 1407 21975800
   PubMed Web of Science ®Google Scholar
• Fridell RA Qiu D Valera L Wang C Rose RE Gao M Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052 J Virol 2011 85 14 7312 7320 21593143
   PubMed Web of Science ®Google Scholar
• Foster TL Belyaeva T Stonehouse NJ Pearson AR Harris M All three domains of the hepatitis C virus nonstructural NS5A protein contribute to RNA binding J Virol 2010 84 18 9267 9277 20592076
   PubMed Web of Science ®Google Scholar
• Scheel TK Rice CM Understanding the hepatitis C virus life cycle paves the way for highly effective therapies Nat Med 2013 19 7 837 849 23836234
   PubMed Web of Science ®Google Scholar
• Elazar M Cheong KH Liu P Greenberg HB Rice CM Glenn JS Amphipathic helix-dependent localization of NS5A mediates hepatitis C virus RNA replication J Virol 2003 77 10 6055 6061 12719597
   PubMed Web of Science ®Google Scholar
• Tellinghuisen TL Marcotrigiano J Rice CM Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase Nature 2005 435 7040 374 379 15902263
   PubMed Web of Science ®Google Scholar
• Lohmann V Hoffmann S Herian U Penin F Bartenschlager R Viral and cellular determinants of hepatitis C virus RNA replication in cell culture J Virol 2003 77 5 3007 3019 12584326
   PubMed Web of Science ®Google Scholar
• Appel N Zayas M Miller S Essential role of domain III of nonstructural protein 5A for hepatitis C virus infectious particle assembly PLoS Pathog 2008 4 3 e1000035 18369481
   PubMed Web of Science ®Google Scholar
• Gao M Nettles RE Belema M Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect Nature 2010 465 7294 96 100 20410884
   PubMed Web of Science ®Google Scholar
• Pol S Ghalib RH Rustgi VK Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial Lancet Infect Dis 2012 12 9 671 677 22714001
   PubMed Web of Science ®Google Scholar
• Lemm JA O’Boyle D Liu M Identification of hepatitis C virus NS5A inhibitors J Virol 2010 84 1 482 491 19812153
   PubMed Web of Science ®Google Scholar
• Wang C Valera L Jia L Kirk MJ Gao M Fridell RA In vitro activity of daclatasvir on hepatitis C virus genotype 3 NS5A Antimicrob Agents Chemother 2013 57 1 611 613 23089758
   PubMed Web of Science ®Google Scholar
• Wang C Jia L Huang H In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A Antimicrob Agents Chemother 2012 56 3 1588 1590 22203595
   PubMed Web of Science ®Google Scholar
• Pelosi LA Voss S Liu M Gao M Lemm JA Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir Antimicrob Agents Chemother 2012 56 10 5230 5239 22850513
   PubMed Web of Science ®Google Scholar
• Wang C Huang H Valera L Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052 Antimicrob Agents Chemother 2012 56 3 1350 1358 22214777
   PubMed Web of Science ®Google Scholar
• Qiu D Lemm JA O’Boyle DR The effects of NS5A inhibitors on NS5A phosphorylation, polyprotein processing and localization J Gen Virol 2011 92 Pt 11 2502 2511 21795470
   PubMed Web of Science ®Google Scholar
• Lee C Ma H Hang JQ The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A nonstructural viral protein Virology 2011 414 1 10 18 21513964
   PubMed Web of Science ®Google Scholar
• Targett-Adams P Graham EJ Middleton J Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: insights into compound modes of action J Virol 2011 85 13 6353 6368 21507963
   PubMed Web of Science ®Google Scholar
• Guedj J Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life Proc Natl Acad Sci. USA 2013 110 3991 3996 23431163
   PubMed Web of Science ®Google Scholar
• Fridell RA Qiu D Wang C Valera L Gao M Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system Antimicrob Agents Chemother 2010 54 9 3641 3650 20585111
   PubMed Web of Science ®Google Scholar
• Nettles RE Gao M Bifano M Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1 Hepatology 2011 54 6 1956 1965 21837752
   PubMed Web of Science ®Google Scholar
• Fridell RA Wang C Sun JH Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations Hepatology 2011 54 6 1924 1935 21809362
   PubMed Web of Science ®Google Scholar
• Bifano M Sevinsky H Persson A Single-dose pharmacokinetics of daclatasvir (DCV; BMS-790052) in subjects with hepatic impairment compared with healthy subjects Presented at: 62nd Annual Meeting of the American Association for the Study of Liver Diseases November 6–9, 2011 San Francisco, CA
   Google Scholar
• Fontana RJ Hughes EA Appelman H Hindes R Dimitrova D Bifano M Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation Liver Transpl 2012 18 9 1053 1059 22706796
   PubMed Web of Science ®Google Scholar
• Lok AS Gardiner DF Lawitz E Preliminary study of two antiviral agents for hepatitis C genotype 1 N Engl J Med 2012 366 3 216 224 22256805
   PubMed Web of Science ®Google Scholar
• Sulkowski MS Gardiner DF Rodriguez-Torres M AI444-040 Study Group Sustained virologic response with daclatasvir plus sofosbuvir ± ribavirin (RBV) in chronic HCV genotype (GT) 1-infected patients who previously failed telaprevir (TVR) or boceprevir (BOC) Presented at: 48th Annual Meeting of the European Association for the Study of the Liver April 24–28, 2013 Amsterdam, The Netherlands
   Google Scholar
• Sulkowski MS Gardiner DF Rodriguez-Torres M AI444040 Study Group High rate of sustained virologic response with the all-oral combination of daclatasvir (NS5A inhibitor) plus sofosbuvir (nucleotide NS5B inhibitor), with or without ribavirin, in treatment-naive patients chronically infected with HCV GT 1, 2, or 3 Hepatology 2012 56 1516 1517
   Web of Science ®Google Scholar
• Chayama K Takahashi S Toyota J Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders Hepatology 2012 55 3 742 748 21987462
   PubMed Web of Science ®Google Scholar
• Suzuki Y Ikeda K Suzuki F Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options J Hepatol 2013 58 4 655 662 23183526
   PubMed Web of Science ®Google Scholar
• Karino Y Toyota J Ikeda K Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir J Hepatol 2013 58 4 646 654 23178977
   PubMed Web of Science ®Google Scholar
• Sun JH O’Boyle Ii DR Zhang Y Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5A replication complex inhibitor, BMS-790052 Hepatology 2012 55 6 1692 1699 22234905
   PubMed Web of Science ®Google Scholar
• Galmozzi E Aghemo A Colombo M Low rates of naturally occurring resistant variants to the NS5A inhibitor daclatasvir in HCV-1 null responders Hepatology 2013 57 5 2087 22745013
   PubMed Web of Science ®Google Scholar
• Suzuki F Sezaki H Akuta N Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b J Clin Virol 2012 54 4 352 354 22658798
   PubMed Web of Science ®Google Scholar
• Plaza Z Soriano V Vispo E Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor Antivir Ther (Lond) 2012 17 5 921 926 22436385
   PubMed Web of Science ®Google Scholar
• Asselah T Sofosbuvir-based interferon-free therapy for patients with HCV infection J Hepatol Epub July 24 2013
   Web of Science ®Google Scholar
• Chae HB Park SM Youn SJ Direct-acting antivirals for the treatment of chronic hepatitis C: open issues and future perspectives Scientific World Journal 2013 2013 704912 23844410
   PubMed Web of Science ®Google Scholar
• Gentile I Borgia F Buonomo AR Castaldo G Borgia G A novel promising therapeutic option against hepatitis C virus: an oral nucleotide NS5B polymerase inhibitor sofosbuvir Curr Med Chem 2013 20 30 3733 3742 23848533
   PubMed Web of Science ®Google Scholar